Custom cancer treatment: one shot before surgery decides Year-Long drug plan
NCT ID NCT04013854
Summary
This study is testing a personalized approach to prevent melanoma skin cancer from coming back after surgery. Patients first receive a single dose of the drug nivolumab before their operation. Based on how well the tumor responds to that single dose, doctors then assign a specific, year-long drug regimen after surgery to try to keep the cancer away. The trial is for adults with stage III melanoma that can be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Lancaster General Hospital
Lancaster, Pennsylvania, 17601, United States
Conditions
Explore the condition pages connected to this study.